- OncoSil Medical (OSL) treats its first patient in Italy with the Oncosil device, its flagship product for pancreatic cancer treatment
- The first patient treatment was carried out at the San Camilo-Forlanini Hospital in Rome, a significant milestone for the company as it paves the way for further adoption of the device
- OSL CEO and MD Nigel Lange says it looks forward to providing future patients with hope through the use of its device
- He noted more than 12,000 patients a year in Italy don’t survive their cancer diagnosis, representing a significant opportunity as an option for patients with pancreatic cancer
- Shares in OSL are down 7.14 per cent and trading at 1.3 cents at 1:30 pm AEST
OncoSil Medical (OSL) has treated its first patient in Italy with the Oncosil device, its flagship product for pancreatic cancer treatment.
The patient was treated at the San Camillo-Forlanini Hospital in Rome, marking a milestone for the company as it paves the way for further adoption of the device across Italy and reinforces its growing prominence throughout Europe.
“It is a significant achievement to treat our first patient in Italy and we look forward to providing hope to patients in this country with a poor prognosis from cancer of the pancreas,” OSL CEO and Managing Director Nigel Lange said.
“Every year in Italy, more than 12,000 patients do not survive their cancer diagnosis and we are pleased to commence treatments to improve the recognition of the OncoSil device as an option for patients with pancreatic cancer.”
San Camillo-Forlanini Hospital Director General Narciso Mostarda said the research, innovation and courage of professionals to come up with new ways for fighting complex or very complex diseases was paramount.
“There is a real need for building new ways to attack the tumour itself,” he said.
Mr Mostarda said the contribution of professionals was fundamental to reaching this goal.
Shares in OSL are down 7.14 per cent and trading at 1.3 cents at 1:30 pm AEST.